These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15988911)

  • 1. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
    Leitch HA; Connors JM
    Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
    Treon SP; Raje N; Anderson KC
    Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
    J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotypic vaccination in B-cell malignancies.
    Bianchi A; Massaia M
    Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
    Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
    Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
    Vose J
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders.
    Milosević DB
    J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
    Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
    Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
    Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
    Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccines against haematological malignancies.
    Stevenson FK; King CA; Spellerberg MB; Zhu D; Rice J; Sahota S; Thompsett A; Radl J; Hamblin TJ
    Haematologica; 1999 Jun; 84 Suppl EHA-4():11-3. PubMed ID: 10907456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.
    King CA; Spellerberg MB; Zhu D; Rice J; Sahota SS; Thompsett AR; Hamblin TJ; Radl J; Stevenson FK
    Nat Med; 1998 Nov; 4(11):1281-6. PubMed ID: 9809552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.